ESR1 and ductal breast carcinoma in situ: All of the models of DCIS (MCF10.DCIS, SUM102, SUM225) used in the present study lack ER and PR expression and represent aggressive disease for which conventional anti-estrogen therapies (including tamoxifen and raloxifene) would not be used.